Back to Resource Library
Webinar Description:Hundreds of institutions now have access to commercial CAR T cells, but in parallel many institutions globally are looking to implement a more decentralized approach using partnerships or commercially available vectors and devices. Here we describe what is required to get these programs up and running and how they can be implemented globally – including in developing countries.Key Learning Objectives:
Implementing a New Clinical CAR T Program: Manufacturing Your Own!Webinar 1 of the ISCT Americas Webinar Series. Presented by the ISCT North America and South & Central America Regional Executive CommitteesSponsored by Miltenyi Biotec
Patrick Hanley, PhDISCT North America Regional Vice-PresidentChildren's National Health SystemWashington, DC, United States
Milena Soares, BSc, PhDISCT SCA Regional Vice-President ElectFundação Oswaldo CruzRio De Janeiro, Brazil
Martin Bonamino, PhDNational Cancer Institute of Brazil (INCA)Rio de Janeiro, Brazil
Implementing a CAR-T initiative at the Brazilian National Cancer Institute
Martin Bonamino received his PhD in biological chemistry from the Federal University of Rio de Janeiro in 2004. Since 2005 he lead a group developing cell and gene immunotherapies at the Brazilian National Cancer institute in Rio de Janeiro. They were the pioneer group in Brazil in CAR-T cell development and have contributed to the field by developing protocols for cost-effective generation of such cell products. From 2015 he also joined the Fundação Oswaldo Cruz, the largest health institution in Brazil, where he co-coordinate the recently established institutional program for cancer research.
In addition to contributing to the cancer, tumor immunology, synthetic biology and gene therapy fields, he had the opportunity to contribute to the establishment of the regulatory framework for cell and gene therapies in Brazil as a member of the advisory committee of ANVISA, the Brazilian regulatory agency.
Nirav Shah, MDMedical College of WisconsinMadison, USA
Building a New CART T Program
Nirav Shah, MD, MSHP, is an Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in lymphoma, CAR-T cell therapy, and stem cell transplant at Froedtert Hospital. He graduated with honors and Alpha Omega Alpha Honor Society membership from the University of Illinois at Chicago College of Medicine in 2008. He then completed his Internal Medicine residency at Massachusetts General Hospital in Boston, Massachusetts in 2011. Post-residency, he took a position at Northwestern Memorial Hospital in Hospitalist medicine before proceeding to the University of Pennsylvania where he completed both hematology/oncology fellowship and a Master’s degree in Health Policy research in 2015. His research focus involves the development of novel CAR therapies for B-cell malignancies and is currently leading several trials utilizing a bispecific CAR20.19 construct.
© 2021 ISCT. All rights reserved.
Site by eConverse Media